TriangleNeoadjuvant Lenvatinib (NCT05319015)
Neoadjuvant Lenvatinib trial for Renal Cell Carcinoma (NCT05319015). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with renal cell carcinoma extending into the inferior vena cava as a level II–IV tumor thrombus. Limited metastases are allowed; prior systemic anticancer treatment is excluded.
The idea: oral lenvatinib blocks blood-vessel growth signals, while intravenous pembrolizumab releases an immune brake. Twelve weeks of preoperative treatment precede planned kidney and thrombus removal. Pembrolizumab continues after surgery. Researchers assess tumor control, progression and surgical complications.
This phase 2 study plans 30 patients. Vitaly Margulis leads it at UT Southwestern in Dallas, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.